Chemical Biology and Drug Design

NOVEMBER 20, 2023

Sorafenib and glimepiride simultaneously downregulated c-Maf protein expression to induce G1 phase arrest and apoptosis in myeloma cells. Given the abnormally high expression of c-Maf in most MM patients, targeting c-Maf presents an attractive therapeutic approach for treating MM malignancies.

Small Molecule 100

Small Molecule Protein Expression FDA Approval FDA 100

Conversations in Drug Development Trends

MAY 30, 2024

Other researchers are investigating approaches that use AAV-mediated trophic support and antibody-based therapies, such as vaccines and small molecule drugs, to modify various protein expressions. For example, antioxidant-based treatments may counter the higher levels of oxidative stress in ALS patients.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

DrugBank

JULY 24, 2024

These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. Similarly, PROTACs can target and degrade overexpressed proteins, offering a way to overcome drug resistance, a common issue in cancer treatment.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Broad Institute

SEPTEMBER 26, 2024

Recently published literature has identified three proteins (Lap2β, H3K9me3, and HP1γ) that exhibit decreased expression in aged fibroblasts and a “senescence cocktail” of small molecules that have been observed to reduce the expression of these chromatin proteins in a way that models aged cells.

Small Molecule 52

Small Molecule Protein Expression Disease Science 52

The Pharma Data

SEPTEMBER 2, 2020

Other data to be presented will show high treatment persistence and strong adherence for patients treated with OCREVUS compared to other DMTs in real-world settings. Fenebrutinib is designed to be a highly selective small molecule and is the only reversible (non-covalent) BTK inhibitor currently in Phase III development in MS.

Clinical Trials 52

Clinical Trials Treatment Disease Therapies 52

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

SEPTEMBER 8, 2020

Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 11-13 September 2020.

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52